Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620748 · ClinicalTrials.gov registry record · Phase 1
Use of Intravenous Tranexamic Acid During Myomectomy
A Phase 1 study of Fibroids and Hemorrhage/Blood Loss During Myomectomies, sponsored by George Washington University.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT02620748: Completed Phase 1 study of Fibroids and Hemorrhage/Blood Loss During Myomectomies, sponsored by George Washington University.
NCT02620748 is a Phase 1 study of Fibroids and Hemorrhage/Blood Loss During Myomectomies that has completed, run by George Washington University. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02620748, a Phase 1 study of Fibroids and Hemorrhage/Blood Loss During Myomectomies, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effect of the early administration of intravenous (IV) Tranexamic acid (TA) on perioperative bleeding (as defined by measured intraoperative estimated blood loss (EBL), change in pre and post-operative hemoglobin (Hb), and frequency of blood transfusions) in women undergoing a myomectomy.
Primary Outcome
the volume of blood loss will be measured at end of surgery.
Conditions Studied
Interventions
- DRUG Tranexamic Acid
- OTHER Saline Solution
Study Locations (1)
District of Columbia
- Medical Faculty Associates - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-02-22 |
| Phase | Phase 1 |
What the finished NCT02620748 record still lists
NCT02620748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 2 conditions, with Fibroids appearing as the primary indexed condition, and to 2 interventions - of which Tranexamic Acid is the first listed.
NCT02620748 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02620748 about?
NCT02620748 is a clinical study titled "Use of Intravenous Tranexamic Acid During Myomectomy". The purpose of this study is to determine the effect of the early administration of intravenous (IV) Tranexamic acid (TA) on perioperative bleeding (as defined by measured intraoperative estimated blood loss (EBL), change in pre and post-operative hemoglobin (Hb), and frequency of blood transfusions...
What is the current status of trial NCT02620748?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-03. Estimated completion is 2018-02-22.
What conditions does trial NCT02620748 study?
This clinical trial studies the following conditions: Fibroids, Hemorrhage/Blood Loss During Myomectomies.
What interventions are being tested in trial NCT02620748?
The interventions under investigation include: Tranexamic Acid (DRUG), Saline Solution (OTHER).
Who is sponsoring clinical trial NCT02620748?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02620748 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibroids
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02620748's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia